EORTC 1709: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma
Indication :

Glioblastome nouvellement diagnostiqué


Sponsor :

EORTC


Phase :

III


Ligne :

1


Traitement :

Temozolimide (TMZ) + radiotherapy (RT) +/_ Marizomib followed by adjuvant TMZ +/- Marizomib


Spécificités :

Archival tumor tissue available at screening (1 paraffin block or 24 unstained slides minimum)


Site :

CHUV, HUG


Contact(s) :
Dr Andreas Hottinger
Investigateur Principal

CHUV

Rue du Bugnon 46
Lausanne
1011

+41 21 314 65 41
andreas.hottinger@chuv.ch
Dr Anna PATRIKIDOU
Investigateur Principal

Hôpitaux Universitaire de Genève
Oncologie

Rue Gabrielle Perret Gentil, 4
1211
Genève

+33795536009
Anna.Patrikidou@hcuge.ch

Primary objective :
  • Establish the impact of marizomib in combination with TMZ/RT impact on overall survival.

Inclusion criteria :
  1. Histologically confirmed newly diagnosed glioblastoma (WHO grade IV)
  2. Tumor resection (gross total or partial), or biopsy only
  3. Availability of FFPE tumor block or 24 unstained slides for MGMT analysis
  4. Patient must be eligible for standard TMZ/RT + TMZ
  5. Karnofsky performance score (KPS) ≥ 70
  6. Recovered from effects of surgery, postoperative infection and other complications of surgery (if any)
  7. The patient is at least 18 years of age on day of signing informed consent
  8. Stable or decreasing dose of steroids for at least 1 week prior to inclusion
  9. The patient has a life expectancy of at least 3 months
  10. Patient has undergone a brain MRI within 14 days of randomization but after intervention (resection or biopsy)
  11. The patient shows adequate organ functions as assessed by the specified laboratory values within 2 weeks prior to randomization defined as adequate bone marrow, renal and hepatic function within the following ranges:
    • WBC ≥ 3×10*9/L
    • ANC ≥ 1.5×10*9/L
    • Platelet count of ≥ 100×10*9/L independent of transfusion
    • Hemoglobin ≥ 10 g/dl
    • Total Bilirubin ≤ 1.5 ULN
    • ALT, AST, alkaline phosphatase (ALP) ≤ 2.5 × ULN
    • Serum creatinine < 1.5 x ULN or creatinine clearance (CrCl) > 30 mL/min(using the Cockcroft-Gault formula)
  12. Women of child bearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to the first dose of study treatment.
  13. Patients of childbearing / reproductive potential must agree to use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1 percent per year) when used consistently and correctly. Patients must also agree not to donate sperm during the study and for 6 months after receiving the last dose of study treatment.
  14. Women who are breast feeding must agree to discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
  15. Ability to take oral medication
  16. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
  17. Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.